Abstract
Bridging theory and practice remains the very own endeavor of clinicians; such bridging is aimed at expelling science from the ‘niches’ and at establishing the upside down of the scientific mode. The suggested steady on-going transition of the phenotypes of biological systems objects has become an object of institutionalized scientific interest to ultimately conceive transient evolutionarily confined systems stages or even heterogeneity among metastatic tumor sites. Providing methodologies for reconstructing the situative communicative expression of systems participators is the novel field of evolution-adjusted tumor pathophysiology. The evolution theory is based on the assumption that biological processes are interwoven with communication and represented and reproduced through communication acts to facilitate communicative expression: A tumor system not only consists of diverse cell types and pathways—termed ‘tumor systems objects’—but also comprises all components of action insofar that these components are oriented in terms of diverse cell types. The components of action are organized in communication acts. Communication within a biological system is closely linked to descriptively accessible ‘learning’ processes, contingency programming, adoption of the players, and the systems objects within a tumor system. An evolution theory should operationalize the ‘metabolism’, facilitating the spinoff of novel systems functions. Furthermore, such a theory is aimed at covering some practical, i.e., diagnostically and therapeutically relevant issues to convince the scientific community that the evolutionary concept lacks proper appreciation, both for diagnostic and therapeutic issues. For many diseases, such as metastatic tumors that have undergone countless years of evolution, a stepwise and evolution-adjusted therapy rather than drastic therapeutic interventions based on theme-dependent knowledge may be an alternative for achieving medical improvements. Thus, paradox situations of cellular rationalization, deformation, and communication processes need to be decoded or, in other words, it is necessary to uncover inconsistencies within tumor cell compartments or distinct topologies of aggregated action effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Reichle A (2009) Tumor systems need to be rendered usable for a new action-theoretical abstraction: the starting point for novel therapeutic options. Curr Cancer Ther Rev 5:232–242
Gatenby RA, Vincent TL (2003) An evolutionary model of carcinogenesis. Cancer Res 63(19):6212–6220
Reichle A (2010) Bridging theory and therapeutic practice: from generalized disease models to particular patients. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3. doi:10.1007/978-90-481-9531-2_1
Reichle A, Hildebrandt GC (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron 1(1):159–170
Reichle A, Hildebrandt GC (2009) Principles of modular tumor therapy. Cancer Microenviron 2(Suppl 1):227–237
Barham J (2012) Normativity, agency, and life. Stud Hist Philos Biol Biomed Sci 43(1):92–103. (Epub 2011 Jun 21)
Reichle A, Vogelhuber M, Feyerabend S, Suedhoff T, Schulze M, Hubner J, Oberneder R, Baier M, Ruebel A, Birkholz K, Bakhshandeh-Bath A, Andreesen R (2011) A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, and low-dose treosulfan: combined anti-inflammatory, immunomodulatory, and angiostatic treatment in patients (pts) with castration-refractory prostate cancer (CRPC). J Clin Oncol 29:(suppl; abstr 4599)
Reichle A, Hildebrandt GC (2010) The comparative uncovering of tumor systems biology by modularly targeting tumor-associated inflammation. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 4. Springer, pp 287–303. doi:10.1007/978-90-481-9531-2_13
Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ (2011) Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 71(15):5090–5100
Paulitschke V et al (2010) Secretome proteomics, a novel tool for biomarkers discovery and for guiding biomodulatory therapy approaches. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 6. Springer, pp 405–431. doi:10.1007/978-90-481-9531-2_21
Kiessling F, Lederle W et al (2010) Early detection of systems response: molecular and functional imaging of angiogenesis. In: Reichle A (ed) From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 6. Springer, pp 385–403. doi:10.1007/978-90-481-9531-2_20
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. (Review)
Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38(4):576–589
Sarrazin S, Sieweke M (2011) Integration of cytokine and transcription factor signals in hematopoietic stem cell commitment. Semin Immunol 23(5):326–334
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Reichle, A. (2013). Turning Upside Down the Mode of Science to Emphasize and Harness the Impact of Environmental Communication. In: Reichle, A. (eds) Evolution-adjusted Tumor Pathophysiology:. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6866-6_14
Download citation
DOI: https://doi.org/10.1007/978-94-007-6866-6_14
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6865-9
Online ISBN: 978-94-007-6866-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)